AnaptysBio Spinoff News Sends Stock Up More Than 30%
AnaptysBio (ANAB) announced on Monday, September 29, 2025 that it plans to spinoff its biopharma programs from its royalty and milestone assets by the end of 2026. Investors cheered the move: AnaptysBio stock is up more than 30% to around $31.75 on heavy volume. According to the press release, the transaction would create two independent companies: A royalty… Read More »